Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease ...Middle East

TOKYO, June 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the US Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event...

Hence then, the article about astellas announces fda update on the fortis clinical trial of at845 in adults with late onset pompe disease was published today ( Monday 27/06/2022 - 02:52 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease )

Also on site :

• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Saturday, January 17, 2026
• Maison Margiela’s 'Elegant' Duo Perfume Set Makes Fragrance Layering Easy, and It’s Just $30 at Kohl’s 
• Royal Caribbean Extends Pause at Private Caribbean Resort Through 2026—Here’s What Cruisers Are Getting Instead